Gamidor specializes in solutions for Women’s health and especially cervical cancer prevention and early detection by cytological and molecular testing. Most cases of cervical cancer can be attributable to HPV (Human Papilloma Virus) infections. Routine cervical screening has been shown to greatly reduce both the number of cervical cancers diagnosed and deaths from the disease.
The most common screening method used in Israel today is PAP testing, cytological testing, with Liquid-based cytology (LBC), aimed to detect potentially pre-cancerous and cancerous processes in the cervix. Gamidor represents the world leading supplier of PAP testing, and has great experience with the systems and vials. The systems are used countrywide in many of the HMOs and hospitals in Israel.
Another approach for cervical cancer screening is Molecular testing to identify high-risk HPV types. Gamidor Markets and distributes state-of-the-art technology and assays for HPV screening, that allow sensitive, automated results. Gamidor also offers systems for full genotyping of Low and high risk HPV genotypes.
We work closely with Gynecologists and Laboratories in order to provide the best support to our clients.